Reports Q2 revenue $1.22B, consensus $1.62B. Adjusted EBITDA was $209M for the second quarter of 2024, as compared to $179M for the second quarter of 2023, an increase of $30M , primarily due to the increase in sales, as noted above, partially offset by an investment in launch products, including MIEBO and XIIDRA. “Our continued growth is being fueled by a relentless focus on selling and operational excellence, and a commitment to innovation that defined our past and will dictate our future,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “That commitment was on full display in the second quarter, with the approval or launch of three innovative products across three distinct businesses, announced over 12 days.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch Health price target lowered to $7 from $8 at Truist
- Bausch + Lomb price target raised to $20 from $18 at RBC Capital
- Bausch + Lomb initiated with an Outperform at Raymond James
- Bausch + Lomb price target raised to $15.50 from $15 at Evercore ISI
- Bausch + Lomb Showcases Innovations at EuDEC 2024